Oxidative stress mediated mitochondrial and vascular lesions as markers in the pathogenesis of alzheimer disease

Current Medicinal Chemistry

Volumn 21, Issue 19, 2014, Pages 2208-2217

  Aliev, G ^a,b   Priyadarshini, M ^c   Reddy, V P ^d   Grieg, N H ^e   Kaminsky, Y ^f   Cacabelos, R ^g   Ashraf, Ghulam Md ^h   Jabir, N R ^h   Kamal, M A ^h   Nikolenko, V N ⁱ   Zamyatnin Jr , A A ⁱ   Benberin, V V ^j   Bachurin, S O ^k  

^a GALLY International Biomedical Research Consulting LLC   (United States)

^b University of Atlanta   (United States)

^c ALIGARH MUSLIM UNIVERSITY   (India)

^d MISSOURI UNIVERSITY OF SCIENCE AND TECHNOLOGY   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f INSTITUTE OF THEORETICAL AND EXPERIMENTAL BIOPHYSICS   (Russian Federation)

^g CAMILO JOSÉ CELA UNIVERSITY   (Spain)

^h KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

ⁱ I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

^j Street Orunbor 2   (Kazakhstan)

^k INSTITUTE OF PHYSIOLOGICALLY ACTIVE COMPOUNDS   (Russian Federation)

more..

Author keywords

Alzheimer disease; Antioxidants; Cerebrovascular pathology; Mitochondria; Neurodegeneration; Oxidative stress

Indexed keywords

ANTIOXIDANT; MITOCHONDRIAL DNA; MITOCHONDRIAL ENZYME; NITRIC OXIDE SYNTHASE;

ALZHEIMER DISEASE; ANTIOXIDANT ACTIVITY; ARTICLE; BLOOD VESSEL WALL; BRAIN MITOCHONDRION; BRAIN PERFUSION; BRAIN TISSUE; CELL HYPOXIA; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; DEMENTIA; DISEASE ASSOCIATION; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HUMAN; NEUROPATHOLOGY; NONHUMAN; OXIDATIVE STRESS; VASCULAR ENDOTHELIUM; VASCULAR LESION; ANIMAL; BRAIN; METABOLISM; MITOCHONDRION; VASCULARIZATION;

ALZHEIMER DISEASE; ANIMALS; ANTIOXIDANTS; BRAIN; HUMANS; MITOCHONDRIA; OXIDATIVE STRESS;

EID: 84899821025     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867321666131227161303     Document Type: Article

References (159)

1. Kim, H.A.; Miller, A.A.; Drummond, G.R.; Thrift, A.G.; Arumugam, T.V.; Phan, T.G.; Srikanth, V.K.; Sobey, C.G. Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress. Naunyn- Schmiedeberg's Arch. Pharmacol., 2012, 385(10), 953-959.
2. Priyadarshini, M.; Kamal, M.A.; Greig, N.H.; Realef, M.; Abuzenadah, A.M.; Chaudhary. A.G.A.; Damanhouri, G.A. Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase. CNS Neurol. Disord. Drug Targets, 2012,11(4), 482-489.
3. Reddy, V.P.; Beyaz, A. Inhibitors of the Maillard reaction and AGE breakers as therapeutics for multiple diseases. Drug Discov. Today, 2006, 11(13 & 14), 646-654.
4. Cho, S.J.; Roman, G.; Yeboah, F.; Konishi, Y. The road to advanced glycation end products: a mechanistic perspective. Curr. Med. Chem., 2007, 14(15), 1653-1671.
5. Reddy, V,P.; Zhu, X.; Perry, G.; Smith, M.A. Oxidative Stress in Diabetes and Alzheimer's Disease. J. Alzheimer's Dis., 2009, 16(4), 763-774.
6. Bennett, S.A.L.; Pappas, B.A.; Stevens, W.D.; Davidson, C.M.; Fortin, T.; Chen, J. Cleavage of amyloid precursor protein elicited by chronic cerebral hypoperfusion. Neurobiol. Aging, 2000, 21(2), 207-214.
7. Liu, H.; Zhang, J. Cerebral Hypoperfusion and Cognitive Impairment: The Pathogenic Role of Vascular Oxidative Stress. Int. J. Neurosci., 2012, 122(9), 494-499.
8. Sochocka, M.; Koutsouraki, E.S.; K, G.A.; Leszek, J. Vascular Oxidative Stress and Mitochondrial Failure in the Pathobiology of Alzheimer's Disease: New Approach to Therapy. CNS Neurol. Disord. Drug Targets, 2013, 12(6), 870-881.
9. de la Torre, J.C. A turning point for Alzheimer's disease? BioFactors, 2012, 38(2), 78-83.
10. Peng, Y.; Xu, S.; Chen, G.; Wang, L.; Feng Y.; Xiaoliang Wang, X. l-3-n-Butylphthalide Improves Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. J. Pharmacol. Exp. Ther., 2007, 321(3), 902-910.
11. Zhu, X.; Smith, M.A.; Honda, K.; Aliev, G.; Moreira, P.I.; Nunomura, A.; Casadesus, G.; Harris, P.L.R.; Siedlak,S.L.; Perry, G. Vascular oxidative stress in Alzheimer disease. J. Neurol. Sci., 2007, 257(1-2), 240-246.
12. Aliev, G.; Smith, M.A.; Seyidov, D.; Neal, M.L.; Lamb, B.T.; Nunomura, A.; Gasimov E.K.; Vinters, H.V.; Perry, G.; LaManna, J.C.; Friedland, R.P. The role of oxidative stress in the pathophysiology of cerebrovascular lesions in Alzheimer's disease. Brain Pathol., 2002, 12(1), 21-35.
13. Aliev, G.; Gasimov, E.; Obrenovich, M.E.; Fischbach, K.; Shenk, J.C.; Smith, M.A.; Perry, G. Atherosclerotic lesions and mitochondria DNA deletions in brain microvessels: implication in the pathogenesis of Alzheimer's disease. Vasc. Health Risk Manag., 2008, 4(3), 721-730.
14. Aliev, G.; Obrenovich, M.E.; Reddy, V.P.; Shenk, J.C.; Moreira, P.I.; Nunomura, A.; Zhu, X.; Smith, M.A.; Perry, G. Antioxidant therapy in Alzheimer's disease: theory and practice. Mini Rev. Med. Chem., 2008, 8(13), 1395-1406.
15. Kotsovolis, G.; Kallaras, K. The role of endothelium and endogenous vasoactive substances in sepsis. Hippokratia, 2010, 14(2), 88-93.
16. Liu, H.; Xing, A.; Wang, X.; Liu, G.; Li, L. Regulation of β- amyloid level in the brain of rats with cerebrovascular hypoperfusion. Neurobiol. Aging, 2012, 33(4), 826.e31-42.
17. Austin, B.P.; Nair, V.A.; Meier, T.B.; Xu, G.; Rowley, H.A.; Carlsson, C.M.; Johnson, S.C.; Prabhakaran, V. Effects of hypoperfusion in Alzheimer's disease. J. Alzheimer's Dis., 2011, 26(3), 123-133.
18. Aliev, G.; Palacios, H.H.; Walrafen, B.; Lipsitt, A.E.; Obrenovich, M.E.; Morales, L. Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. Int. J. Biochem. Cell Biol., 2009, 41(10), 1989-2004.
19. de la Torre, J.C. Cerebrovascular and cardiovascular pathology in Alzheimer's disease. Int. Rev. Neurobiol., 2009, 84, 35-48.
20. Cepinskas, G.; Wilson, J.X. Inflammatory response in microvascular endothelium in sepsis: role of oxidants. J. Clin. Biochem. Nutr., 2008, 42(3), 175-184.
21. Lum, H.; Roebuck, K.A. Oxidant stress and endothelial cell dysfunction. Am. J. Physiol. Cell. Physiol., 2001, 280(4), C719-C741.
22. Aliev, G.; Palacios, H.H.; Lipsitt, A.E.; Fischbach, K.; Lamb, B,T.; Obrenovich, M.E.; Morales L, Gasimov, E.; Bragin, V. Nitric oxide as an initiator of brain lesions during the development of Alzheimer disease. Neurotox. Res., 2009, 16(3), 293-305.
23. Gandhi, S.; Abramov, A.Y. Mechanism of oxidative stress in neurodegeneration. Oxid. Med. Cell Longev., 2012, 2012, 428010.
24. Keller, J.N.; Schmitt, F.A.; Scheff, S.W.; Ding, Q.; Chen, Q.; Butterfield, D.A.; Markesbery, W.R. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology, 2005, 64(7), 1152-1156.
25. Ferreiro, E.; Baldeiras, I.; Ferreira, I.L.; Costa, R.O.; Rego, A.C.; Pereira, C.F.; Oliveira, C.R. Mitochondrial- and endoplasmic reticulum-associated oxidative stress in Alzheimer's disease: from pathogenesis to biomarkers. Int. J. Cell. Biol., 2012, 2012, 735206.
26. Smith, M.A.; Vasák, M.; Knipp, M.; Castellani, R.J.; Perry, G. Dimethylargininase, a nitric oxide regulatory protein, in Alzheimer disease. Free Radic. Biol. Med., 1998, 25(8), 898-902.
27. Prasad, M.R.; Lovell, M.A.; Yatin, M.; Dhillon, H.; Markesbery, W.R. Regional membrane phospholipid alterations in Alzheimer's disease. Neurochem. Res., 1998, 23(1), 81-88.
28. Prelli, F.; Castaño, E.M.; van Duinen, S.G.; Bots, G.T.; Luyendijk, W.; Frangione, B. Different processing of Alzheimer's beta-protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. Biochem. Biophys. Res. Commun., 1988, 151(3), 1150-1155.
29. Bourdel-Marchasson, I.; Delmas-Beauvieux, M.C.; Peuchant, E.; Richard-Harston, S.; Decamps, A.; Reignier, B.; Emeriau, J.P.; Rainfray, M. Antioxidant defences and oxidative stress markers in erythrocytes and plasma from normally nourished elderly Alzheimer patients. Age Ageing, 2001, 30(3), 235-241.
30. Polidori, M.C.; Mecocci, P. Plasma susceptibility to free radicalinduced antioxidant consumption and lipid peroxidation is increased in very old subjects with Alzheimer disease. J. Alzheimer's Dis., 2002, 4(6), 517-522.
31. Zafrilla, P.; Mulero, J.; Xandri, J.M.; Santo, E.; Caravaca, G.; Morillas, J.M. Oxidative stress in Alzheimer patients in different stages of the disease. Curr. Med. Chem., 2006, 13(9), 1075-1083.
32. Bermejo, P.; Martín-Aragón, S.; Benedí, J.; Susín, C.; Felici, E.; Gil, P.; Ribera, J.M.; Villar, A.M. Peripheral levels of glutathione and protein oxidation as markers in the development of Alzheimer's disease from Mild Cognitive Impairment. Free Radic. Res., 2008, 42(2), 162-170.
33. Isobe, C.; Abe, T.; Terayama, Y. Levels of reduced and oxidized coenzyme Q-10 and 8-hydroxy-2'-deoxyguanosine in the CSF of patients with Alzheimer's disease demonstrate that mitochondrial oxidative damage and/or oxidative DNA damage contributes to the neurodegenerative process. J. Neurol., 2010, 257(3), 399-404.
34. Baldeiras, I.; Santana, I.; Proença, M.T.; Garrucho, M.H.; Pascoal, R.; Rodrigues, A.; Duro, D.; Oliveira, C.R. Oxidative damage and progression to Alzheimer's disease in patients with mild cognitive impairment. J. Alzheimer's Dis., 2010, 21(4), 1165-1177.
35. Mecocci, P.; MacGarvey, U.; Beal, M.F. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann. Neurol., 1994, 36(5), 747-751.
36. Lee, S.H.; Kim, I.; Chung, B.C. Increased urinary level of oxidized nucleosides in patients with mild-to-moderate Alzheimer's disease. Clin. Biochem., 2007, 40(13-14), 936-938.
37. Abe, T.; Tohgi, H.; Isobe, C.; Murata, T.; Sato, C. Remarkable increase in the concentration of 8-hydroxyguanosine in cerebrospinal fluid from patients with Alzheimer's disease. J. Neurosci. Res., 2002, 70(3), 447-450.
38. Nunomura, A.; Perry, G.; Aliev, G.; Hirai, K.; Takeda, A.; Balraj, E.K.; Jones, P.K.; Ghanbari, H.; Wataya, T.; Shimohama, S.; Chiba, S.; Atwood, C.S.; Petersen, R.B.; Smith, M.A. Oxidative damage is the earliest event in Alzheimer disease. J. Neuropathol. Exp. Neurol., 2001, 60(8), 759-767.
39. Mangialasche, F.; Polidori, M.C.; Monastero, R.; Ercolani, S.; Camarda, C.; Cecchetti, R.; Mecocci, P. Biomarkers of oxidative and nitrosative damage in Alzheimer's disease and mild cognitive impairment. Ageing Res. Rev., 2009, 8(4), 285-305.
40. Smith, M.A.; Rottkamp, C.A.; Nunomura, A.; Raina, A.K.; Perry, G. Oxidative stress in Alzheimer's disease. Biochim. Biophys. Acta, 2000, 1502(1), 139-144.
41. Aliev, G.; Li, Y.; Palacios, H.H.; Obrenovich, M.E. Oxidative stress induced mitochondrial DNA deletion as a hallmark for the drug development in the context of the cerebrovascular diseases. Recent Patents Cardiovasc. Drug Discov., 2011, 6(3), 222-241.
42. Smith, M.A.; Taneda, S.; Richey, P.L.; Miyata, S.; Yan, S.D.; Stern, D.; Sayre, L.M.; Monnier, V.M.; Perry, G. Advanced Maillard reaction end products are associated with Alzheimer disease pathology. Proc. Natl. Acad. Sci. USA, 1994, 91(12), 5710-5714.
43. Cirillo, R.; Aliev, G.; Hornby, E.J.; Prosdocimi, M. Endothelium as a therapeutical target in peripheral occlusive arterial diseases: consideration for pharmacological interventions. Pharmacol. Res., 1994, 29(4), 293-311.
44. Cirillo, R.; Salvatico, E.; Aliev, G.; Prosdocimi, M. Effect of cloricromene during ischemia and reperfusion of rabbit hindlimb: evidence for an involvement of leukocytes in reperfusion-mediated tissue and vascular injury. J. Cardiovasc. Pharmacol., 1992, 20(6), 969-975.
45. Sala, A.; Aliev, G.M.; Rossoni, G.; Berti, F.; Buccellati, C.; Burnstock, G.; Folco, G.; Maclouf, J. Morphological and functional changes of coronary vasculature caused by transcellular biosynthesis of sulfidopeptide leukotrienes in isolated heart of rabbit. Blood, 1996, 87(5), 1824-1832.
46. Salvatico, E.; Aliev, G.M.; Novello, D.; Prosdocimi, M. Functional depression of isolated perfused rat heart mediated by activated leukocytes: protective effect of cloricromene. J. Cardiovasc. Pharmacol., 1994, 24(4), 638-647.
47. Salmina, A.B.; Inzhutova, A.I.; Malinovskaya, N.A.; Petrova, M.M. Endothelial dysfunction and repair in Alzheimer-type neurodegeneration: neuronal and glial control. J. Alzheimer's Dis., 2010, 22(1), 17-36.
48. Aliev. G.; Cirillo, R.; Salvatico, E.; Paro, M.; Prosdocimi, M. Changes in vessel ultrastructure during ischemia and reperfusion of rabbit hindlimb: implications for therapeutic intervention. Microvasc. Res., 1993, 46(1), 65-76.
49. Aliev, G.; Burnstock, G. Watanabe rabbits with heritable hypercholesterolaemia: a model of atherosclerosis. Histol. Histopathol., 1998, 13(3), 797-817.
50. Stewart-Lee, A.L.; Ferns, G.A.; Anggard, E.E. Differences in onset of impaired endothelial responses and in effects of vitamin E in the hypercholesterolemic rabbit carotid and renal arteries. J. Cardiovasc. Pharmacol., 1995, 25(6), 906-913.
51. Kalaria, R.N. The blood-brain barrier and cerebrovascular pathology in Alzheimer's disease. Ann. N. Y. Acad. Sci., 1999, 893, 113-125.
52. Kalaria, R.N. The role of cerebral ischemia in Alzheimer's disease. Neurobiol. Aging, 2000, 21(2), 321-330.
53. Price, J.M.; Sutton, E.T.; Hellermann, A.; Thomas, T. beta- Amyloid induces cerebrovascular endothelial dysfunction in the rat brain. Neurol. Res., 1997, 19(5), 534-538.
54. Bennett, S.; Grant, M.M.; Aldred, S. Oxidative stress in vascular dementia and Alzheimer's disease: a common pathology. J. Alzheimer's Dis., 2009, 17(2), 245-257.
55. Bruce-Keller, A.J.; Gupta, S.; Parrino, T.E.; Knight, A.G.; Ebenezer, P.J.; Weidner, A.M.; LeVine, H.; Keller, J.N.; Markesbery, W.R. NOX activity is increased in mild cognitive impairment. Antioxid. Redox Signal., 2010, 12(12), 1371-1382.
56. Dietrich, H.H.; Xiang, C.; Han, B.H.; Zipfel, G.J.; Holtzman, D.M. Soluble amyloid-beta, effect on cerebral arteriolar regulation and vascular cells. Mol. Neurodegener., 2010, 5(15), 1-12.
57. Iadecola, C.; Park, L.; Capone, C. Threats to the Mind Aging, Amyloid, and Hypertension. Stroke, 2009, 40(3), S40-S44.
58. Iadecola, C.; Zhang, F.; Niwa, K.; Eckman, C.; Turner, S.K.; Fischer, E.; Younkin S, Borchelt, D.R.; Hsiao, K.K.; Carlson, G.A. SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein. Nat. Neurosci., 1999, 2(2), 157-161.
59. Niwa, K.; Carlson, G.A.; Iadecola, C. Exogenous A beta1-40 reproduces cerebrovascular alterations resulting from amyloid precursor protein overexpression in mice. J. Cereb. Blood Flow Metab., 2000, 20(12), 1659-1668.
60. Grammas, P.; Moore, P.; Weigel, P.H. Microvessels from Alzheimer's Disease Brains Kill Neurons in Vitro. Am. J. Pathol., 1999, 154(2), 337-342.
61. Hawkes, C.A.; Härtig, W.; Kacza, J.; Schliebs, R.; Weller, R.O.; Nicoll, J.A.; Carare, R.O. Perivascular drainage of solutes is impaired in the ageing mouse brain and in the presence of cerebral amyloid angiopathy. Acta Neuropathol. (Berl.), 2011, 121(4), 431-443.
62. Weller, R.O.; Subash, M.; Preston, S.D.; Mazanti, I.; Carare, R.O. Perivascular drainage of amyloid-beta peptides from the brain and its failure in cerebral amyloid angiopathy and Alzheimer's disease. Brain Pathol.(Zurich, Switzerland), 2008, 18(2), 253-266.
63. Tillement, L.; Lecanu, L.; Papadopoulos, V. Alzheimer's disease: Effects of amyloid on mitochondria. Mitochondrion, 2011, 11(1), 13-21.
64. Boche, D.; Zotova, E.; Weller, R.O.; Love, S.; Neal, J.W.; Pickering, R.M.; Wilkinson, D.; Holmes, C.; Nicoll, J.A. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain. Brain, 2008, 131(12), 3299-3310.
65. Readnower, R.D.; Sauerbeck, A.D.; Sullivan, P.G. Mitochondria, Amyloid, and Alzheimer's Disease. Int. J. Alzheimers Dis., 2011, 2011. doi: 10.4061/2011/104545.
66. Palacios, H.H.; Yendluri, B.B.; Parvathaneni, K.; Shadlinski, V.B.; Obrenovich, M.E.; Leszek, J.; Gokhman, D.; Gsiorowski, K.; Bragin, V.; Aliev, G. Mitochondrion-specific antioxidants as drug treatments for Alzheimer disease. CNS Neurol. Disord. Drug Targets, 2011, 10(2), 149-162.
67. Schulz, J.B.; Matthews, R.T.; Klockgether, T.; Dichgans, J.; Beal, M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol. Cell. Biochem., 1997, 174(1-2), 193-197.
68. Beckman, K.B.; Ames, B.N. The free radical theory of aging matures. Physiol. Rev., 1998, 78(2), 547-581.
69. Beckman, K.B.; Ames, B.N. Mitochondrial aging: open questions. Ann. N. Y. Acad. Sci., 1998, 854, 118-127.
70. Beckman, K.B.; Ames, B.N. Endogenous oxidative damage of mtDNA. Mutat. Res., 1999, 424(1-2), 51-58.
71. Wallace, D.C. Mitochondrial diseases in man and mouse. Science, 1999, 283(5407), 1482-1488.
72. Fiskum, G.; Murphy, A.N.; Beal, M.F. Mitochondria in neurodegeneration: acute ischemia and chronic neurodegenerative diseases. J. Cereb. Blood Flow Metab., 1999, 19(4), 351-369.
73. Hirai, K.; Aliev, G.; Nunomura, A.; Fujioka, H.; Russell, R.L.; Atwood, C.S.; Johnson, A.B.; Kress, Y.; Vinters, H.V.; Tabaton, M.; Shimohama, S.; Cash, A.D.; Siedlak, S.L.; Harris, P.L.; Jones, P.K.; Petersen, R.B.; Perry, G.; Smith, M.A. Mitochondrial abnormalities in Alzheimer's disease. J. Neuroscience, 2001, 21(9), 3017-3023.
74. Beal, M.F. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol., 1995, 38(3), 357-366.
75. Bonilla, E.; Tanji, K.; Hirano, M.; Vu, T.H.; DiMauro, S.; Schon, E.A. Mitochondrial involvement in Alzheimer's disease. Biochim. Biophys. Acta., 1999, 1410(2), 171-182.
76. Aliev, G.; Smith, M.A.; Obrenovich, M.E.; de la Torre, J.C.; Perry, G. Role of vascular hypoperfusion-induced oxidative stress and mitochondria failure in the pathogenesis of Azheimer disease. Neurotox. Res., 2003, 5(7), 491-504.
77. Al-Abdulla, N.A.; Martin, L.J. Apoptosis of retrogradely degenerating neurons occurs in association with the accumulation of perikaryal mitochondria and oxidative damage to the nucleus. Am. J. Pathol., 1998, 153(2), 447-456.
78. Yao, J.; Irwin, R.W.; Zhao, L.; Nilsen, J.; Hamilton, R.T.; Brinton, R.D. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2009, 106(34), 14670-14675.
79. Mancuso, M.; Coppedè. F.; Murri. L.; Siciliano, G. Mitochondrial cascade hypothesis of Alzheimer's disease: myth or reality? Antioxid. Redox Signal., 2007, 90(10), 1631-1646.
80. Parker, W.D. Jr.; Filley, C.M.; Parks, J.K. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology, 1990, 40(8), 1302-1203.
81. Tieu, K.; Perier, C.; Vila, M.; Caspersen, C.; Zhang, H-P.; Teismann, P.; Jackson-Lewis, V.; Stern, D.M.; Yan, S.D.; Przedborski, S. L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Ann. Neurol., 2004, 56(1), 51-60.
82. Maurer, I.; Zierz, S.; Möller, H.J. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol. Aging, 2000, 21(3), 455-462.
83. Du, H.; Yan, S.S. Mitochondrial permeability transition pore in Alzheimer's disease: cyclophilin D and amyloid beta. Biochim. Biophys. Acta, 2010, 1802(1), 198-204.
84. Wang, X.; Su, B.; Siedlak, S.L.; Moreira, P.I.; Fujioka, H.; Wang, Y.; Casadesus, G.; Zhu, X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc. Natl. Acad. Sci. USA, 2008, 105(49), 19318-19323.
85. Cho, D-H.; Nakamura, T.; Fang, J.; Cieplak, P.; Godzik, A.; Gu, Z.; Lipton, S.A. S-nitrosylation of Drp1 mediates beta-amyloidrelated mitochondrial fission and neuronal injury. Science, 2009, 324(5923), 102-105.
86. Yao, J.; Taylor, M.; Davey, F.; Ren, Y.; Aiton, J.; Coote, P.; Fang, F.; Chen, J.X.; Yan, S.D.; Gunn-Moore, F.J. Interaction of amyloid binding alcohol dehydrogenase/Abeta mediates up-regulation of peroxiredoxin II in the brains of Alzheimer's disease patients and a transgenic Alzheimer's disease mouse model. Mol. Cell Neurosci., 2007, 35(2), 377-382.
87. Lustbader, J.W.; Cirilli, M.; Lin, C.; Xu, H.W.; Takuma, K.; Wang, N.; Caspersen, C.; Chen, X.; Pollak, S.; Chaney, M.; Trinchese, F.; Liu, S.; Gunn-Moore, F.; Lue, L.F.; Walker, D.G.; Kuppusamy, P.; Zewier, Z.L.; Arancio, O.; Stern, D.; Yan, S.S.; Wu, H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science, 2004, 304(5669), 448-452.
88. Vanová, O.G.; Baiak, L.; Kaparová, S.; Kucharská, J.; Palacios, H.H.; Horeck, J.; Aliev, G. In vivo and in vitro assessment of brain bioenergetics in aging rats. J. Cell. Mol. Med., 2010, 14(11), 2667-2674.
89. Horeck, J.; Baciak, L.; Kasparová, S.; Pacheco, G.; Aliev, G.; Vancová, O. Minimally invasive surgical approach for three-vessel occlusion as a model of vascular dementia in the rat-brain bioenergetics assay. J. Neurol. Sci., 2009, 283(1-2), 178-181.
90. Wallace, D.C. Mitochondrial DNA in aging and disease. Sci. Am., 1997, 277(2), 40-47.
91. Bobba, A.; Petragallo, V.A.; Marra, E.; Atlante, A. Alzheimer's proteins, oxidative stress, and mitochondrial dysfunction interplay in a neuronal model of Alzheimer's disease. Int. J. Alzheimers Dis., 2010, 2010. doi: 10.4061/2010/621870.
92. Coskun, P.E.; Wyrembak, J.; Derbereva, O.; Melkonian, G.; Doran, E.; Lott, I.T.; Head, E.; Cotman, C.W.; Wallace, D.C. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J. Alzheimer's Dis., 2010, 20(2), S293-S310.
93. Mosconi, L.; Berti, V.; Swerdlow, R.H.; Pupi. A.; Duara, R.; de Leon, M. Maternal transmission of Alzheimer's disease: prodromal metabolic phenotype and the search for genes. Hum. Genom., 2010, 4(3), 170-193.
94. Kalaria, R.N.; Akinyemi, R.; Ihara, M. Does vascular pathology contribute to Alzheimer changes? J. Neurol. Sci., 2012, 322(1-2), 141-147.
95. de la Torre, J.C. Alzheimer disease as a vascular disorder: nosological evidence. Stroke, 2002, 33(4), 1152-1162.
96. De Jong, G.I.; De Vos, R.A.; Steur, E.N.; Luiten, P.G. Cerebrovascular hypoperfusion: a risk factor for Alzheimer's disease? Animal model and postmortem human studies. Ann. N. Y. Acad. Sci., 1997, 826, 56-74.
97. de la Torre, J.C. Hemodynamic consequences of deformed microvessels in the brain in Alzheimer's disease. Ann. N. Y. Acad. Sci., 1997, 826, 75-91.
98. Friston, K.J.; Frackowiak, R.S. Cerebral function in aging and Alzheimer's disease: the role of PET. Electroencephalogr. Clin. Neurophysiol. Suppl., 1991, 42, 355-365.
99. Kumar, A.; Schapiro, M.B.; Haxby, J.V.; Grady, C.L.; Friedland, R.P. Cerebral metabolic and cognitive studies in dementia with frontal lobe behavioral features. J. Psychiatr. Res., 1990, 24(2), 97-109.
100. Galle J, Bengen J, Schollmeyer P, Wanner C. Impairment of endothelium-dependent dilation in rabbit renal arteries by oxidized lipoprotein(a). Role of oxygen-derived radicals. Circulation, 1995, 92(6), 1582-1589.
101. de la Torre, J.C.; Stefano, G.B. Evidence that Alzheimer's disease is a microvascular disorder: the role of constitutive nitric oxide. Brain Res. Brain Res. Rev., 2000, 34(3), 119-136.
102. Meguro, K.; Blaizot, X.; Kondoh, Y.; Le Mestric, C.; Baron, J.C.; Chavoix, C. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Brain, 1999, 122(8), 1519-1531.
103. Jagust, W.J.; Friedland, R.P.; Budinger, T.F.; Koss, E.; Ober, B. Longitudinal studies of regional cerebral metabolism in Alzheimer's disease. Neurology, 1988, 38(6), 909-912.
104. Orsucci, D.; Mancuso, M.; Ienco, E.C.; Simoncini, C.; Siciliano, G.; Bonuccelli, U. Vascular factors and mitochondrial dysfunction: a central role in the pathogenesis of Alzheimer's disease. Curr. Neurovasc. Res., 2013, 10(1), 76-80.
105. de la Torre, J.C. Pathophysiology of neuronal energy crisis in Alzheimer's disease. Neurodegener. Dis., 2008, 5(3-4), 126-132.
106. Murray, I.V.J.; Proza, J.F.; Sohrabji, F.; Lawler, J.M. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med. (Maywood), 2011, 236(7), 772-782.
107. de la Torre, J.C. Critically attained threshold of cerebral hypoperfusion: can it cause Alzheimer's disease? Ann. N. Y. Acad. Sci., 2000, 903, 424-436.
108. de la Torre, J.C. Alzheimer's disease prevalence can be lowered with non-invasive testing. J. Alzheimer's Dis., 2008, 14(3), 353-359.
109. Hofman, A.; Ott, A.; Breteler, M.M.; Bots, M.L.; Slooter, A.J.; van Harskamp, F.; van Duijn, C.N.; Van Broeckhoven, C.; Grobbee, D.E. Atherosclerosis, apolipoprotein E, and prevalence of dementia and Alzheimer's disease in the Rotterdam Study. Lancet, 1997, 349(9046), 151-154.
110. Schneider, J.A.; Boyle, P.A.; Arvanitakis, Z.; Bienias, J.L.; Bennett, D.A. Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. Ann. Neurol., 2007, 62(1), 59-66.
111. Whitehead S.N.; Massoni, E.; Cheng, G.; Hachinski, V.C.; Cimino, M.; Balduini, W.; Cechetto, D.F. Triflusal reduces cerebral ischemia induced inflammation in a combined mouse model of Alzheimer's disease and stroke. Brain. Res., 2010, 1366, 246-256.
112. Román, G.C.; Royall, D.R. A diagnostic dilemma: is "Alzheimer's dementia" Alzheimer's disease, vascular dementia, or both? Lancet Neurol., 2004, 3(3), 141.
113. Guglielmotto, M.; Aragno, M.; Autelli, R.; Giliberto, L.; Novo, E.; Colombatto, S.; Danni, O.; Parola, M.; Smith, M.A.; Perry, G.; Tamagno, E.; Tabaton, M. The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1alpha. J. Neurochem., 2009, 108(4), 1045-1056.
114. Wen, Y.; Yu, W.H.; Maloney, B.; Bailey, J.; Ma, J.; Marié, I.; Maurin, T.; Wang, L.; Figueroa, H.; Herman, M.; Krishnamurthy, P.; Liu, L.; Planel, E.; Lau, L.F.; Lahiri, D.K.; Duff, K. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron., 2008, 57(5), 680-690.
115. Weinbrecht, P.; Longmuir, I.; Knopp, J.; Mills, M. Cerebral microcirculatory changes during exposure to hypoxia. Adv. Exp. Med. Biol., 1987, 215, 259-263.
116. Mironov, V.; Hritz, M.A.; LaManna, J.C.; Hudetz, A.G.; Harik, S.I. Architectural alterations in rat cerebral microvessels after hypobaric hypoxia. Brain Res., 1994, 660(1), 73-80.
117. Chávez, J.C.; Agani, F.; Pichiule, P.; LaManna, J.C. Expression of hypoxia-inducible factor-1alpha in the brain of rats during chronic hypoxia. J. Appl. Physiol., 2000, 89(5), 1937-1942.
118. Aliev, G.; Smith, M.A.; de la Torre, J.C.; Perry, G. Mitochondria as a primary target for vascular hypoperfusion and oxidative stress in Alzheimer's disease. Mitochondrion, 2004, 4(5-6), 649-663.
119. Aliev, G.; Palacios, H.H.; Gasimov, E.; Obrenovich, M.E.; Morales, L.; Leszek, J.; Bragin, V.; Herrera, A.S.; Dmitry Gokhman Oxidative Stress Induced Mitochondrial Failure and Vascular Hypoperfusion as a Key Initiator for the Development of Alzheimer Disease. Pharmaceuticals, 2010, 3(1), 158-187.
120. Siedlak, S.L.; Casadesus, G.; Webber, K.M.; Pappolla, M.A.; Atwood, C.S.; Smith, M.A.; Perry, G. Chronic antioxidant therapy reduces oxidative stress in a mouse model of Alzheimer's disease. Free Radic. Res., 2009, 43(2), 156-164.
121. Ames, B.N. Delaying the mitochondrial decay of aging. Ann. N. Y. Acad. Sci., 2004, 1019, 406-411.
122. Ames, B.N.; Liu, J. Delaying the mitochondrial decay of aging with acetylcarnitine. Ann. N. Y. Acad. Sci., 2004, 1033, 108-116.
123. Liu, J.; Head, E.; Gharib, A.M.; Yuan, W.; Ingersoll, R.T.; Hagen, T.M.; Cotman, C.W.; Ames, B.N. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or Ralpha -lipoic acid. Proc. Natl. Acad. Sci. USA, 2002, 99(4), 2356-2361.
124. Aliev, G.; Liu, J.; Shenk, J.C.; Fischbach, K.; Pacheco, G.J.; Chen, S.G.; Obrenovich, M.E.; Ward, W.F.; Richardson, A.G.; Smith, M.A.; Gasimov, E.; Perry, G.; Ames, B.N. Neuronal mitochondrial amelioration by feeding acetyl-L-carnitine and lipoic acid to aged rats. J. Cell Mol. Med., 2009, 13(2), 320-333.
125. Milgram, N.W.; Araujo, J.A.; Hagen, T.M.; Treadwell, B.V.; Ames, B.N. Acetyl-L-carnitine and alpha-lipoic acid supplementation of aged beagle dogs improves learning in two landmark discrimination tests. FASEB J., 2007, 21(13), 3756-3762.
126. Liu, J.; Head, E.; Kuratsune, H.; Cotman, C.W.; Ames, B.N. Comparison of the effects of L-carnitine and acetyl-L-carnitine on carnitine levels, ambulatory activity, and oxidative stress biomarkers in the brain of old rats. Ann. N. Y. Acad. Sci., 2004, 1033, 117-131.
127. Shenk, J.C.; Liu, J.; Fischbach, K.; Xu, K.; Puchowicz, M.; Obrenovich, M.E.; Gasimov, E.; Alvarez, L.M.; Ames, B.N.; LaManna, J.C.; Aliev, G. The effect of acetyl-L-carnitine and Ralpha- lipoic acid treatment in ApoE4 mouse as a model of human Alzheimer's disease. J. Neurol. Sci., 2009, 283(1-2), 199-206.
128. Mahley, R.W.; Weisgraber, K.H.; Huang, Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2006, 103(15), 5644-5651.
129. Reiman, E.M.; Caselli, R.J.; Chen, K.; Alexander, G.E.; Bandy, D.; Frost, J. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Proc. Natl. Acad. Sci. USA, 2001, 98(6), 3334-3339.
130. Aliev, G.; Castellani, R.J.; Petersen, R.B.; Burnstock, G.; Perry, G.; Smith, M.A. Pathobiology of familial hypercholesterolemic atherosclerosis. J. Submicrosc. Cytol. Pathol., 2004, 36(3-4), 225-240.
131. Long, J.; Gao, F.; Tong, L.; Cotman, C.W.; Ames, B.N.; Liu, J. Mitochondrial decay in the brains of old rats: ameliorating effect of alpha-lipoic acid and acetyl-L-carnitine. Neurochem. Res., 2009, 34(4), 755-763.
132. Liu, J.; Killilea, D.W.; Ames, B.N. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid. Proc. Natl. Acad. Sci. USA, 2002, 99(4), 1876-1881.
133. Liu, J.; Atamna, H.; Kuratsune, H.; Ames, B.N. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann. N. Y. Acad. Sci.USA, 2002, 959, 133-166.
134. McManus, M.J.; Murphy, M.P.; Franklin, J.L. The mitochondriatargeted antioxidant MitoQ prevents loss of spatial memory retention and early neuropathology in a transgenic mouse model of Alzheimer's disease. J. Neuroscience, 2011, 31(44), 15703-15715.
135. James, A.M.; Sharpley, M.S.; Manas, A-RB.; Frerman, F.E.; Hirst, J.; Smith, R.A.J.; Murphy, M.P. Interaction of the mitochondria-targeted antioxidant MitoQ with phospholipid bilayers and ubiquinone oxidoreductases. J. Biol. Chem., 2007, 282(20), 14708-14718.
136. Lu, C.; Zhang, D.; Whiteman, M.; Armstrong, J.S. Is antioxidant potential of the mitochondrial targeted ubiquinone derivative MitoQ conserved in cells lacking mtDNA? Antioxid. Redox Signal., 2008, 10(3), 651-660.
137. Manczak, M.; Mao, P.; Calkins, M.J.; Cornea, A.; Reddy, A.P.; Murphy, M.P.; Szeto, H.H.; Park, B.; Reddy, P.H. Mitochondriatargeted antioxidants protect against amyloid-beta toxicity in Alzheimer's disease neurons. J. Alzheimer's Dis., 2010, 20(2), S609-S631.
138. Feng, Y.; Wang, X. Antioxidant therapies for Alzheimer's disease. Oxid. Med. Cell Longev., 2012, 2012. doi: 10.1155/2012/472932.
139. Horeck, J.; Gvozdjáková, A.; Kucharská, J.; Obrenovich, M.E.; Palacios, H.H.; Li, Y.; Vanová, O.; Aliev G. Effects of coenzyme Q and creatine supplementation on brain energy metabolism in rats exposed to chronic cerebral hypoperfusion. Curr. Alzheimer Res., 2011, 8(8), 868-875.
140. Anekonda, T,S.; Reddy, P.H. Can herbs provide a new generation of drugs for treating Alzheimer's disease? Brain Res. Brain Res. Rev., 2005, 50(2), 361-376.
141. Bragin, V.; Chemodanova, M.; Bragin, I.; Dzhafarova, N.; Mescher, I.; Chernyavskyy, P.; Obrenovich, M.E.; Palacios, H.H.; Aliev, G. A 60-month follow-up of a naturalistic study of integrative treatment for real-life geriatric patients with depression, dementia and multiple chronic illnesses. Open J. Psychiatr., 2012, 2, 129-140.
142. Aliev, G.; Shenk, J.C.; Fischbach, K.; Perry, G. Stem cell niches as clinical targets: the future of anti-ischemic therapy? Nat. Clin. Pract. Cardiovasc. Med., 2008, 5(9), 590-591.
143. Halliwell, B. Role of free radicals in the neurodegenerative diseases: Therapeutic implications for antioxidant treatment. Drugs Aging, 2001, 18(9), 685-716.
144. Gilgun-Sherki, Y.; Melamed, E.; Offen, D. Antioxidant treatment in Alzheimer's disease: current state. J. Mol. Neurosci., 2003, 21(1), 1-11.
145. Ali, S.K.; Hamed, A.R.; Soltan, M.M.; Hegazy, U.M.; Elgorashi, E.E.; Ibrahim A El-Garf, I.A.; Hussein, A.A. In-vitro evaluation of selected Egyptian traditional herbal medicines for treatment of alzheimer disease. BMC Complement. Altern. Med., 2013, 13, 121.
146. Calkins, M.J.; Manczak, M.; Reddy, P.H. Mitochondria-targeted antioxidant SS31 prevents amyloid beta-induced mitochondrial abnormalities and synaptic degeneration in Alzheimer's disease. Pharmaceuticals, 2012, 5, 1103-1119.
147. Reddy, P,H. Mitochondrial oxidative damage in aging and Alzheimer's disease: implications for mitochondrially targeted antioxidant therapeutics. J. Biomed. Biotechnol., 2006, 2006(3), 31372. doi: 10.1155/jbb/2006/31372.
148. Santos, R.X.; Correia, S.C.; Zhu, X.; Smith, M.A.; Moreira, P.I.; Castellani, R.J.; Nunomura, A.; Perry, G. Mitochondrial DNA oxidative damage and repair in aging and Alzheimer's disease. Antioxid. Redox Signal., 2013, 18(18), 2444-2457.
149. Reddy, P.H.; Tripathi, R.; Troung, Q.; Tirumala, K.; Reddy, T.P.; Anekonda, V.; Shirendeb, U.P.; Calkins, M.J.; Reddy, A.P.; Mao, P.; Manczak, M. Abnormal mitochondrial dynamics and synaptic degeneration as early events in Alzheimer's disease: Implications to mitochondria-targeted antioxidant therapeutics. Biochimica Biophysica Acta, 2012, 1822(5), 639-649.
150. Cornelli, U. Treatment of Alzheimer's Disease with a Cholinesterase Inhibitor Combined with Antioxidants. Neurodegenerat. Dis., 2010, 7(1-3), 193-202.
151. Lu, P.H.; Edland, S.D.; Teng, E.; Tingus, K.; Petersen, R.C.; Cummings, J.L. Donepezil delays progression to AD in MCI subjects with depressive symptoms. Neurology, 2009, 72(24), 2115-2121.
152. Morris, M.C.; Evans, D.A.; Tangney, C.C.; Bienias, J.L.; Wilson, R.S.; Aggarwal, N.T.; Scherr, P.A. Relation of the tocopherol forms to incident Alzheimer disease and to cognitive change. Am. J. Clin. Nutr., 2005, 81(2), 508-514.
153. Jabir, N.R.; Tabrez, S.; Ashraf, G.M.; Shakil, S.; Damanhouri, G.A.; Kamal, M.A. Nanotechnology-based approaches in anticancer research. Int. J. Nanomed., 2012, 7, 4391-4408.
154. Kaminsky, Y.G.; Reddy, V.P.; Ashraf, G.M.; Ahmad, A.; Benberin, V.V.; Kosenko, E.A.; Aliev, G. Age-Related Defects in Erythrocyte 2,3- Diphosphoglycerate Metabolism in Dementia. Aging Dis., 2013, 4(5), 244-255.
155. Aliev, G.; Ashraf G.M.; Kaminsky, Y.G.; Sheikh, I.A.; Sudakov KV, Bachurin SO. Implication of the Nutritional and Non- Nutritional Factors in the Context of Preservation of Cognitive Performance in Demented/ Depressed and Alzheimer Patients. Am. J. Alzheimers Dis. Other Demen., 2013, 8(7), 660-670.
156. Mirza, Z.; Ali, A.; Ashraf, G.M.; Kamal, M.A.; Abuzenadah, A.M.; Choudhary, A.G.A.; Damanhouri, G.A.; Sheikh, I.A. Proteomics approaches to understand linkage between Alzheimer's disease and type 2 diabetes mellitus. CNS Neurol. Disord. Drug Targets, 2013, [Epub ahead of print].
157. Ahmad, A.; Rasheed, N.; Ashraf, G.M.; Kumar, R.; Banu, N.; Khan, F.; Al-Sheeh, M.; Palit, G. Brain region specific monoamine and oxidative changes during restraint stress. Can. J. Neurol. Sci., 2012, 39(3), 311-318.
158. Ahmad, A.; Rasheed, N.; Gupta, P.; Singh, S.; Siripurapu, K.B.; Ashraf, G.M.; Kumar, R.; Chand, K.; Maurya, R.; Banu, N.; Alsheeha, M.; Palit, G. Novel Ocimumoside A and B as anti-stress agents: Modulation of brain monoamines and antioxidant systems in chronic unpredictable stress model in rats. Phytomedicine, 2012, 19, 639-647.
159. Hasan S, Bilal N, Naqvi S, Ashraf GM, Suhail N, Sharma S, Banu N. Multivitamin-mineral and vitamins (E+C) supplementation modulate chronic unpredictable stress induced oxidative damage in brain and heart of mice. Biol. Trace Elem. Res., 2011, 142(3), 589-597.